Funding Research With NIH Grants: A Losing Battle In A Flawed System

Flawed System Author: Arthur E. Sowers Scientists who do research in academic environments must pay for this research from grant money obtained through a highly competitive process that starts with the writing of a grant proposal. Although this process can end successfully if a grant proposal is funded, it more often than not ends with a proposal being rejected. It is widely known that over the last 15 years the average chance that a proposal will be funded has declined from about 50 percent

Written byArthur Sowers
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Flawed System Author: Arthur E. Sowers

Scientists who do research in academic environments must pay for this research from grant money obtained through a highly competitive process that starts with the writing of a grant proposal.

Although this process can end successfully if a grant proposal is funded, it more often than not ends with a proposal being rejected. It is widely known that over the last 15 years the average chance that a proposal will be funded has declined from about 50 percent to about 10 percent or less today. Hence, to get one proposal funded, the average scientist must be constantly writing to produce and submit about 10 proposals. The two-fold question that arises from this situation is: How did this process become so difficult, and can anything be done about it?

In the search for answers, one area to concentrate on is how this process works in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies